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Abstract 
Aims/hypothesis The aim of this study was to evaluate the effects of oxygen consumption-matched 
short-term interval walking training (IWT) vs continuous walking training (CWT) on glycaemic 
control, including glycaemic variability, in individuals with type 2 diabetes. We also assessed 
whether any training-induced improvements in glycaemic control were associated with systemic 
oxidative stress levels. 
Methods Participants (n=14) with type 2 diabetes completed a crossover trial using three 
interventions (control intervention [CON], CWT and IWT), each lasting 2 weeks. These were 
performed in a randomised order (computerised generated randomisation) and separated by washout 
periods of 4 or 8 weeks after CON or training interventions, respectively. Training included ten 
supervised treadmill sessions, lasting 60 min/session, and was performed at the research facility. 
CWT was performed at moderate walking speed (75.6%±2.5% of walking peak oxygen 
consumption [ 2peakOV ]), while IWT was performed as alternating 3 min repetitions at slow (58.9% 
± 2.0% 2peakOV ) and fast (90.0% ± 3.6% 2peakOV ) walking speed. Before and after each 
intervention, the following was assessed: 24 h continuous glucose monitoring (CGM) and urinary 
free 8-iso prostaglandin F2α (8-iso PGF2α; a marker for oxidative stress), physical fitness and body 
composition. Neither participants nor assessors were blinded to the interventions. 
Results No intervention-induced changes were seen in physical fitness or body composition. 
Compared to baseline, IWT reduced mean glucose levels non-significantly (−0.7 ± 0.3 mmol/l, p = 
0.08) and significantly reduced maximum glucose levels (−1.8 ± 0.5 mmol/l, p = 0.04) and mean 
amplitude of glycaemic excursions (MAGE; −1.7 ± 0.4 mmol/l, p = 0.02), whereas no significant 
within-group changes were seen with CON or CWT. Although 8-iso PGF2α was associated with 
minimum glucose levels at baseline, no change in 8-iso PGF2α was seen with any intervention, nor 
were there any associations between changes in 8-iso PGF2α and changes in glycaemic control (p > 
0.05 for all). No adverse effects were observed with any of the interventions. 
Conclusions/interpretation Short-term IWT, but not CWT, improves CGM-derived measures of 
glycaemic control independent of changes in physical fitness and body composition in individuals 
with type 2 diabetes. Systemic oxidative stress levels are unaffected by short-term walking and 
changes in oxidative stress levels are not associated with changes in glycaemic control. 
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Introduction 
Regular physical activity is recommended for individuals with type 2 diabetes and the positive 
effect of physical activity on risk factors for cardiovascular disease in these individuals is well-
documented [1]. The exercise structure is a major determinant for the metabolic benefits seen. In 
this respect, interval training modalities, in which there are alternating periods of high- and low-
intensity exercise, have proven effective [2]. As such, we [3] and others [4, 5] have shown that 
interval training programmes are superior to continuous training programmes matched for total 
energy expenditure for improving cardiovascular risk factors in individuals with metabolic disease, 
or equally effective as continuous training despite a lower time and energy consumption [6]. 
Training-induced improvements in cardiovascular risk factors, including glycaemic control, lipid 
levels and blood pressure, may be mediated by the training per se, or by improvements in body 
composition [1]. In support of this, studies comparing training with weight loss vs training without 
weight loss have found the former to have superior beneficial effects on cardiovascular risk factors 
[7, 8]. Since interval training is associated with better improvements in body composition compared 
with energy expenditure-matched continuous training [3, 9, 10], it is unclear whether the superior 
improvements seen in cardiovascular risk factors with interval training are dependent on the 
training per se, and/or on the differential improvements in body composition. Whether interval 
training improves glycaemic control independent of changes in body composition is clinically 
important, as underlined by the minor or nonexistent weight loss reported in meta-analyses 
evaluating long-term training studies [11, 12]. 
Compared with healthy individuals,  individuals with type 2 diabetes have increased rates of 
cardiovascular mortality [13], which are suggested to be dependent on increased systemic oxidative 
stress [14] and associated systemic inflammation in these patients [15]. Poor glycaemic control is 
associated with increased levels of systemic oxidative stress and inflammation, and it is proposed 
that glucose instability (i.e. large glycaemic variability) is more closely associated with increased 
systemic oxidative stress than mean glucose levels [16, 17]. Moreover, while increased mean blood 
glucose levels are predictive of microvascular disease [18], increased glycaemic variability is more 
predictive of macrovascular complications [19]. Short-term training programmes have previously 
been found to reduce glycaemic variability [20, 21]. Whether these reductions in glycaemic 
variability differ between interval and continuous training programmes and whether such reductions 
in glycaemic variability translate to reduced levels of systemic oxidative stress is unknown. 
Thus, the aim of this study was to assess the effects of interval training vs continuous training on 
glycaemic control, lipid levels and blood pressure in individuals with type 2 diabetes, independent 
of changes in body composition. Moreover, we further aimed to evaluate whether potential 
improvements in glycaemic variability and other measures of glycaemic control were associated 
with decreased levels of oxidative stress. We tested the hypotheses that compared with continuous 
training, interval training induces greater improvements in glycaemic control, including reduced 
glycaemic variability, independent of changes in body composition, and that these improvements 
are associated with decreased systemic oxidative stress. 
 
Methods 
Participants Individuals with type 2 diabetes [22], with a BMI >18 kg/m2 but <40 kg/m2, were 
recruited onto the study. Exclusion criteria were insulin treatment, smoking, pregnancy, renal 
failure (estimated GFR < 60 ml/min), contraindications to increased levels of physical activity [23] 
and more than moderate levels of maximally moderate-intensity physical activity (> 90 min/week). 
All participants underwent a screening visit consisting of a medical interview and examination, 
completion of a habitual physical activity questionnaire [24], a walking test for peak oxygen 
consumption ( 2peakOV ), with continuous oxygen uptake measurements (Cosmed K4B2; Cosmed, 
Rome, Italy), and a familiarisation test for maximal oxygen consumption ( 2maxOV ). Participants 
gave informed consent before any investigational procedures were performed. Baseline 
characteristics are given in the Results section. The study was approved by the regional ethical 
committee (H-6-2014-043) and is a registered trial (ClinicalTrials.gov registration no. 
NCT02320526). 
 
Study design Participants were included in a crossover study consisting of three interventions, each 
lasting 2 weeks, with investigations being performed before and after each intervention. Between 
interventions, washout periods (8 weeks after training interventions, 4 weeks after control 
intervention [CON]) were applied, wherein participants returned to their habitual activity levels. 
Interventions were performed in a randomised order (computer generated randomisation was 
carried out using www.randomization.com accessed 6 Nov 2014 [for reproduction use seed 18512]) 
and participants were informed about the upcoming intervention at the end of the pre-intervention 
investigation. 
 
Interventions The training interventions consisted of ten fully supervised 60 min walking sessions 
on a treadmill (Katana; Lode, Groningen, the Netherlands). Training was performed 5 days per 
week (every weekday) but not during the weekend. Continuous walking training (CWT) consisted 
of continuous walking with a speed aiming for ~73% of , whereas interval walking training (IWT) 
consisted of alternating cycles of 3 min slow walking (54% of 2peakOV ) and 3 min fast walking 
(89% of 2peakOV ). These intensities have previously been found sustainable in a free-living training 
study [3]. Adequate walking speeds to reach the desired intensities were determined by performing 
continuous measurements of oxygen uptake (Cosmed Quark; Cosmed) during the first and sixth 
walking sessions in each training intervention. These walking speeds were then repeated for the 
following four exercise sessions. All sessions were performed with a heart rate (HR) monitor (Polar 
RC3; Polar, Kempele, Finland) and the rate of perceived exertion (RPE) was reported immediately 
after each session [25]. For CON, participants were instructed to continue their life without any 
changes. 
 
Investigations Investigations were performed over 4 days (days 0–3) immediately before (pre) and 
after (post) each intervention. On day 0, participants reported to the laboratory for initiation of 
continuous glucose monitoring and for provision of a standardised diet. A continuous glucose 
monitor (CGM) glucose sensor (Enlite; Medtronic, Fridley, MN, USA) was inserted into the 
abdominal subcutaneous adipose tissue and connected to a CGM monitor (iPro2; Medtronic). The 
CGM was calibrated four times each day (before main meals and at bedtime) by a glucose meter 
(Contour; Bayer, Basel, Switzerland). Participants went home after being instructed to avoid 
strenuous physical activity, alcohol and caffeine during the next 3 days. Otherwise, they were 
instructed to live as representatively to their normal life as possible. 
On day 1, participants consumed a self-selected and ‘typical diet’ (based on each individual), which 
was registered in a diet record. This diet record was distributed to the participants so that they could 
duplicate the chosen diet on day 1 of subsequent interventions. 
On day 2, participants only consumed a provided, standardised diet; food was divided into three 
equal portions, consumed by participant at 07:00, 13:00 and 19:00 hours. The diet was intended to 
be isoenergetic and was based on the Mifflin St Jeor Equation multiplied by a physical activity level 
of 1.4 metabolic equivalents (METS) [26]. The diet consisted of a nutritional drink (Resource 
Komplett 1.5; Nestlé, Vevey, Switzerland) with a mixed macronutrient composition (15% of energy 
[E%] protein, 55E% carbohydrate, 30E% fat). Moreover, participants collected 24 h urine in a 
plastic container, starting with an empty bladder at 07:00 hours. The plastic container was kept in a 
cooling bag throughout the urine collection period. 
On day 3, participants reported to the laboratory at 07:00 hours, after having fasted (≥ 8 h, water 
excluded). The CGM system was removed and, after a final void, the urine container was collected. 
A blood sample was taken and body mass was assessed. After supine resting, participants were 
offered a small meal, following which a dual-energy x-ray absorptiometry (DXA) scan (Lunar 
Prodigy Advance; GE Healthcare, Madison, WI, USA) was performed followed by blood pressure 
measurements (Microlife BP meter; Microlife, Widnau, Switzerland). Finally, a 2maxOV test was 
performed using a previously described protocol [3]. 
The post-intervention investigations were planned so that the last IWT/CWT training session was 
performed on day 1, between 12:00 hours and 16:00 hours (15–19 h before initiation of urine 
collection). To avoid energy deficit during the IWT/CWT post-intervention investigations, 
participants were given a snack (200 ml nutritional drink, 1255 kJ; Resource Komplett 1.5) 
immediately after the last IWT/CWT session. 
 
Blood and urine sample analyses Blood samples for glucose measurements were collected in 
heparinised syringes and analysed at a bedside platform (ABL 700; Radiometer, Herlev, Denmark). 
For analysis of HbA1c and TNF-α and IFN-γ (pro-inflammatory cytokines), samples were collected 
in EDTA-coated tubes, whereas for high-sensitive C-reactive protein (hs-CRP), insulin and lipids, 
samples were collected in lithium–heparin-coated tubes. All samples were analysed immediately, 
except for those for pro-inflammatory cytokine measurements which were centrifuged (2000 g, 
4°C, 15 min) and stored at ˗80°C until analysis.  
 
HbA1c was analysed using absorption photometry (Tosoh G7; Tosoh, San Francisco, CA, USA), 
insulin was analysed using Electrochemiluminescence immunoassay (Cobas 8000, Roche 
Diagnostics, IN, USA) and lipids were analysed using absorption photometry (Cobas 8000, Roche 
Diagnostics). Pro-inflammatory cytokines were analysed in duplicate, using the V-plex pro-
inflammatory panel (MSD, Rockville, MD, USA). 
 Urine volume was measured and urine aliquots were frozen at ˗80°C until analysis. Urinary 
creatinine was measured via absorption photometry (Cobas 8000, Roche Diagnostics) and urinary 
free 8-iso prostaglandin F2α (8-iso PGF2α), a marker for oxidative stress [16], was assessed in 
triplicate using the 8-Isoprostane ELISA Kit (Cayman Chemicals, Ann Arbor, MI, USA). 
 
Calculations Mean rates of oxygen uptake were calculated during the first and the sixth IWT/CWT 
session. Moreover, the mean rates of oxygen uptake from the last minute of each slow and fast IWT 
interval were calculated during the same IWT sessions. Mean HR was calculated from all 
IWT/CWT sessions and from the last minute of slow and fast IWT intervals. 
Twenty-four-hour CGM measurements, aligned with the urine collection period (from 07:00 hours 
on day 2 to 07:00 hours on day 3), were analysed for mean, minimum and maximum glucose levels, 
time fraction spent in hyperglycaemia (> 10.0 mmol/l) and hypoglycaemia (< 4.0 mmol/l, [27]), and 
mean amplitude of glycaemic excursions (MAGE; a marker for glycaemic variability [28]). The 8-
iso PGF2α level was normalised to urinary creatinine excretion. 
 
Statistics Pre-intervention variables were compared using one-way repeated-measures ANOVA. 
Training variables (IWT vs CWT) were compared using the Student’s paired t test. The adequacy of 
the washout periods was assessed using the Student’s paired t test, comparing pre-intervention 
variables of a given intervention with the pre-intervention variables of the following intervention. 
Intervention-induced differences within interventions were assessed using two-way repeated-
measures (intervention × time) ANOVA. Intervention-induced differences between interventions 
were assessed using one-way repeated-measures ANOVA of the Δ values for each intervention 
(post − pre-intervention). For all ANOVA analyses, Bonferroni post hoc tests were applied to assess 
differences within/between interventions. 
Associations between 8-iso PGF2α and measures of glycaemic control (both baseline and Δ change 
values) were analysed separately for each intervention using linear regression models. Since the 
strength and direction of the associations were uniform between interventions, all values were 
pooled to increase statistical power. For the pooled analyses, we used random intercept models 
including participants as random effects.  Moreover, the associations between changes were 
adjusted for the baseline values of 8-iso PGF2α and measures of glycaemic control, to account for 
regression towards the mean. Residuals were checked for normality and homoscedasticity. 
All participants completed all investigational procedures but due to a CGM sensor failure in one 
individual (CWT post-intervention), ANOVA analyses of the CGM data only includes 13 
individuals. 
All statistical analyses were two-tailed and performed using Prism v6.03 (GraphPad Software, San 
Diego, CA, USA) or Stata v13.1 (STATA Corporation, College Station, TX, USA). Data are 
reported as mean ± SEM unless indicated otherwise. p values < 0.05 were considered significant. 
 
Results 
Participant characteristics Fourteen participants (11 men; aged 65 ± 2 years; years since diabetes 
diagnosis, 9 ± 1; leisure time physical activity, 1201 ± 226 kJ/day) were included in the study. All 
participants continued their usual glucose-lowering medication during the study period (metformin 
[n=14], sulfonylureas [n=3], glucagon-like peptide-1 [GLP-1] analogues [n=3]), with no changes in 
dose or type. Mean dietary energy intake (apart from the extra 1255 kJ on day 1 during the training 
interventions) was 8339 ± 674 and 10117 ± 418 kJ on day 1 and day 2, respectively, with no 
differences within or between interventions (data not shown). 
 
Interventions Two participants missed a single training session in both IWT and CWT resulting in 
a similar training adherence (sessions completed relative to sessions prescribed) of 99% in both 
interventions. 
There was no difference in mean rate of oxygen uptake between CWT (1524 ± 78 ml/min [75.6% ± 
2.5% of 2peakOV ]) and IWT (1513 ± 78 ml/min [75.0% ± 2.5% of 2peakOV ], p > 0.05). Compared 
with the rate of oxygen uptake during CWT, the rate was lower during low-intensity walking 
periods in IWT (1190 ± 62 ml/min [58.9% ± 2.0% of 2peakOV ]) and higher during high-intensity 
walking periods in IWT (1814 ± 99 ml/min [90.0% ± 3.6% of 2peakOV ]) (p<0.001 for both). 
Mean HR was 108 ± 3 bpm during CWT and 109 ± 3 bpm during IWT (p > 0.05), with the HR 
during low-intensity walking periods in IWT (100 ± 2 bpm) being lower, and that during high-
intensity walking periods in IWT (119 ± 3) being higher than the overall CWT HR (p<0.001 for 
both). 
Mean walking speed was faster during CWT (5.0 ± 0.1 km/h) than during IWT (4.7 ± 0.1 km/h, p < 
0.001); however, the slow IWT walking speed (3.4 ± 0.1 km/h) was slower and fast IWT walking 
speed (6.0 ± 0.1 km/h) was faster than CWT walking speed (p < 0.001 for both). Moreover, mean 
walking speed increased from the first to the sixth training session in both CWT (4.8 ± 0.1 vs 5.0 ± 
0.1 km/h, p = 0.001) and IWT (4.6 ± 0.1 vs 4.8 ± 0.1 km/h, p = 0.01). 
Mean RPE was lower in CWT (11.1 ± 0.5 arbitrary units) than in IWT (12.5 ± 0.4 arbitrary units, 
p=0.002). 
 
Physical fitness and body composition No pre-intervention differences were seen in any variables 
related to physical fitness or body composition (p > 0.05 for all comparisons; Table 1). No changes 
in physical fitness (either absolute or relative to body weight) were observed with any intervention, 
nor were there any intervention-induced differences between interventions (p > 0.05 for all 
comparisons). Body mass was non-significantly decreased after the CWT intervention (−0.4 ± 0.2 
kg, p = 0.09). Neither CON nor IWT resulted in changes in body mass and no intervention-induced 
differences between interventions were seen. For all other body composition assessments (fat-free 
mass and total, android and gynoid fat percentage), no intervention-induced changes and no 
intervention-induced differences between interventions were seen (p > 0.05 for all comparisons; 
Table 1). 
 
Glycaemic control No pre-intervention differences were seen in any glycaemic control variables (p 
> 0.05 for all comparisons) (Fig. 1, Table 1). No significant changes in HbA1c or fasting glucose 
were seen with any of the interventions, and no intervention-induced differences between 
interventions were seen for HbA1c (p > 0.05 for all comparisons). Regarding fasting glucose, IWT 
resulted in a significant reduction compared with CON (−0.5 ± 0.2 vs 0.2 ± 0.3 mmol/l, p = 0.04; 
Table 1). 
Mean CGM glucose levels and time spent in hyperglycaemia did not change after CON or CWT 
interventions (p > 0.05) but showed a trend towards decrease after IWT (−0.7 ± 0.3 mmol/l, p = 
0.08 and −9.5 ± 4.1 % of time, p = 0.08, respectively; Fig. 1a,e and Table 1). Maximum CGM 
glucose levels and MAGE did not change after CON or CWT interventions (p > 0.05) but were 
decreased  following IWT (−1.8 ± 0.5 mmol/l, p = 0.04 and ˗1.7 ± 0.4 mmol/l, p = 0.02, 
respectively; Fig. 1 c,f and Table 1). Moreover, IWT resulted in significant reductions in mean and 
maximum CGM glucose levels and time spent in hyperglycaemia compared with CON (CON: 0.5 ± 
0.3 mmol/l [p = 0.04], 1.6 ± 0.7 mmol/l [p = 0.01] and 8.5 ± 3.9 % of time [p = 0.03], respectively; 
Table 1). No changes in minimum CGM glucose levels or time spent in hypoglycaemia were seen 
with any of the interventions, neither were there any intervention-induced differences between 
interventions (p > 0.05 for all comparisons; Fig. 1b,d and Table 1). 
 
Lipids and blood pressure No pre-intervention differences were seen in blood pressure or any 
lipid variables (p > 0.05 for all comparisons; Table 1). IWT reduced total cholesterols (−0.3 ± 0.1 
mmol/l, p=0.03) and triacylglycerol (−0.2 ± 0.1 mmol/l, p=0.02), with no effects of CWT or CON 
on any lipid variables (p>0.05 for all comparisons). Moreover, no intervention-induced differences 
in any lipid variables were seen between any of the interventions (p > 0.05 for all comparisons). No 
change in blood pressure (either systolic or diastolic) was seen with any of the interventions, neither 
were there any intervention-induced differences between interventions (p > 0.05 for all 
comparisons). 
 
Systemic oxidative stress and inflammation No pre-intervention differences were seen in levels 
of 8-iso PGF2α, hs-CRP, TNF-α or IFN-γ (p > 0.05 for all comparisons; Table 1). Moreover, no 
changes in any of these variables were seen with any of the interventions, neither were there any 
intervention-induced differences between interventions (p > 0.05 for all comparisons). 
 
Washout periods Total cholesterol levels were non-significantly higher before IWT than before the 
following intervention (4.3 ± 0.4 mmol/l vs 4.1 ± 0.4 mmol/l, p = 0.06). For all other clinical 
variables mentioned in Table 1, no differences were seen between pre-IWT/CWT values and pre-
intervention values of the following intervention. 
 
Associations between 8-iso PGF2α and glycaemic control Mean and maximum CGM glucose 
levels, time spent in hyperglycaemia and MAGE were not associated with urinary 8-iso PGF2α at 
baseline (Table 2). In contrast, minimum CGM glucose levels were negatively associated with 8-iso 
PGF2α (Fig. 2a and Table 2) and time spent in hypoglycaemia was positively associated with 8-iso 
PGF2α (Fig. 2b and Table 2). These associations were consistent after Bonferroni correction of the p 
values. 
No significant associations between changes in 8-iso PGF2α and changes in measures of glycaemic 
control were found (Table 2). Adjustments for the baseline levels of 8-iso PGF2α and measures of 
glycaemic control did not influence the associations (data not shown). The association between 
changes in 8-iso PGF2α and changes in maximum CGM glucose was borderline significant (p = 
0.06, r2 = 0.09; Table 2) but only before Bonferroni correction. 
 
Discussion 
The main finding from this study is that IWT, but not time duration- and oxygen consumption-
matched CWT, improves CGM-derived measures of glycaemic control including glycaemic 
variability, independent of changes in body composition and physical fitness in individuals with 
type 2 diabetes. This highlights the importance of training pattern in exercise-induced metabolic 
improvements and suggests that the superior effects previously reported after IWT compared with 
CWT are not merely mediated by the differential effects on body composition and/or physical 
fitness [3]. Another important observation from the study is that systemic oxidative stress levels 
were not changed by any of the interventions and that none of the improvements seen in glycaemic 
control after IWT translated to reduced levels of oxidative stress. 
Although covariate analyses have previously indicated that changes in body composition can only 
explain part of IWT-induced improvements in metabolic variables [29], studies have found that 
training interventions with weight loss improve glycaemic control more than training interventions 
without weight loss [7;8]. In this respect, it is interesting that the IWT-induced improvements in 
glycaemic control seen in the current study are fairly similar to those seen in our previous study 
evaluating a 4-month intervention, which also induced robust improvements in body composition 
and physical fitness [3]. Thus, the current study shows that the effects of IWT on glycaemic control 
are largely explained by factors other than IWT-associated improvements in body composition 
and/or physical fitness. Since the last bout of exercise was performed 15–19 h before initiation of 
the CGM measurement period, and since acute exercise may influence insulin sensitivity and 
therefore glycaemic control for up to 48 h [30], it cannot be concluded from the current study 
whether the improvements seen are training-induced or are dependent on the effects of acute 
exercise. However, since a single IWT session does not differentially influence glycaemic control 
during the day after an exercise bout compared with a single CWT session [31], and because CWT 
did not improve any of the glycaemic control variables in the current study, we believe that the 
training-induced improvements mediate the effects on glycaemic control. 
The lack of improvement in metabolic variables with CWT is notable. Whereas we have previously 
found similar results [3, 29, 31], others have reported positive effects for CWT-like interventions 
[32, 33]. Since adherence to the training regime was very high and both the training duration and 
intensity was well controlled, we speculate that the peak exercise intensity during CWT was not 
high enough to elicit positive changes [34]. 
We did not find any significant associations between baseline values/changes in MAGE, mean 
CGM glucose levels or maximum CGM glucose levels and baseline values/changes in 8-iso PGF2α. 
The lack of association between MAGE and 8-iso PGF2α is especially surprising since Monnier et al 
demonstrated a strong relationship between these two variables in individuals with type 2 diabetes 
[16]. The reason for this discrepancy is unclear; compared with the study by Monnier et al, MAGE 
was assessed using the same method and the ELISA kits used to measure 8-iso PGF2α were from the 
same company. Despite the gold standard for measuring 8-iso PGF2α being mass spectrometry [35], 
a comparison between mass spectrometry and enzyme immunoassay-based measurement of 8-iso 
PGF2α has revealed a good correlation between the two methods (r = 0.80 [36]). One difference 
between the studies is that our mean baseline MAGE levels were substantially higher than those 
reported by Monnier et al (6.2 ± 0.3 mmol/l vs 4.2 ± 0.3 mmol/l) and, although no data are 
available, it might be speculated that the linear relationship between MAGE and 8-iso PGF2α 
disappears with higher glycaemic variability. The difference in the number of individuals analysed 
in the two studies (13 vs 21) may also contribute to this discrepancy. Moreover, it must be 
emphasised that there are other studies that have not been able to demonstrate the close association 
between MAGE and 8-iso PGF2α [37, 38]. 
Exploratory analyses indicated an inverse relationship between 8-iso PGF2α and minimum glucose 
levels. Moreover, time spent in hypoglycaemia (glucose <4.0 mmol/l) was positively correlated to 
8-iso PGF2α. These associations are highly clinically relevant, given the suggested relationship 
between oxidative stress and cardiovascular disease [14]. However, it must be noted that CGM 
measurements in the hypoglycaemic range are somewhat inaccurate [39] and therefore our findings 
need to be confirmed in a controlled setting. The causative role of hypoglycaemia in oxidative stress 
is lent support by a study in which a clamp-based investigation in individuals with type 1 diabetes 
showed that while hyperglycaemia itself causes oxidative stress, the increase in oxidative stress 
levels are much higher if the hyperglycaemia is preceded by hypoglycaemia [17]. The authors 
concluded that the body is more vulnerable to hyperglycaemia when it has recently experienced 
hypoglycaemia. Studies examining whether this pattern is also seen in individuals with type 2 
diabetes are needed. 
None of the interventions in the present study resulted in a change in systemic oxidative stress 
levels, and we did not find any significant associations between changes in glycaemic control 
variables and changes in oxidative stress, either when evaluating all interventions or within any of 
the interventions. In that context, it should be noted that exercise may acutely elevate 8-iso PGF2α  
[40]. Whereas this exercise-induced elevation is typically considered to be short-lived and therefore 
not affecting measurements starting 15 h after cessation of the exercise bout [35], we cannot rule 
out that a potential training-induced reduction was outbalanced by a potential acute exercise-
induced elevation in 8-iso PGF2α. Additionally, since diabetes is a condition wherein chronically 
elevated oxidative stress levels develop over years [14], possibly more than 2 weeks of exercise 
training is required to remedy this. Since 4 months of IWT  has been shown to improve glycaemic 
control when compared with CWT [3], and because of the close association between systemic 
oxidative stress and inflammation [15] and the indirect anti-inflammatory effects of exercise as a 
result of training-induced improvements in body composition [41], studies of longer duration are 
warranted to further examine the potential effects of exercise on oxidative stress. 
 
One limitation of the study is that, although no significant baseline differences between 
interventions were seen in any variables measured, we did see numerically higher baseline levels 
for IWT compared with CWT and CON (Table 1). In particular, CGM-derived measures of 
glycaemic control were considerably higher at baseline for CON compared with baseline for IWT. 
While the reason for this is unknown, it may have resulted in regression towards the mean, which 
may have potentiated the effects seen. However, although post hoc analyses adjusted for the 
respective baseline values did decrease some of the effect sizes, all significant improvements in the 
CGM-derived variables observed with IWT were still present after adjustments (data not shown). 
Another limitation is the small sample size for this study. As such, effect sizes in small studies are 
often greater than in larger studies [42]. Also, since the apparent baseline differences in variables 
may have potentially been influenced by the small sample size, our findings should be confirmed in 
a larger study. 
In summary, 2 weeks of IWT, but not oxygen-consumption-matched CWT, improves CGM-derived 
measures of glycaemic control, including glycaemic variability, independent of changes in body 
composition and physical fitness. Although these findings should be confirmed using a larger 
number of participants, they may have implications for the way in which future training 
programmes are structured and recommended for individuals with type 2 diabetes. 
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Table 1 Clinical variables 
Variable CON  CWT  IWT  CON vs IWT (p 
value)  Pre Post  Pre Post  Pre Post  
Physical fitness           
  Absolute 2maxOV  (l/min) 2.25±0.1
8 
2.24±0.14  2.31±0.1
5 
2.31±0.15  2.30±0.1
6 
2.34±0.15   
  Relative 2maxOV  (ml min
˗1 
kg˗1) 
23.8±1.4 23.8±1.3  24.6±1.6 24.8±1.6  24.5±1.5 24.7±1.1   
Body composition           
  Body mass (kg) 96.8±4.7 96.7±4.7  97.7±4.6 97.3±4.6§  97.0±4.6 96.9±4.6   
  Fat-free mass (kg) 61.1±3.3 61.2±3.2  61.6±3.2 61.3±3.1  61.4±3.2 61.7±3.2   
  Total body fat (%) 38.3±1.8 38.1±1.7  38.3±1.6 38.0±1.6  37.8±1.6 37.7±1.6   
  Android fat (%) 48.6±1.6 48.2±1.5  48.5±1.3 48.5±1.4  48.1±1.2 47.7±1.4   
  Gynoid fat (%) 37.4±2.1 37.4±2.2  37.6±1.9 37.8±2.0  37.2±2.0 37.0±2.0   
Lipids (mmol/l)           
  Total cholesterol 4.1±0.3 4.1±0.3  4.2±0.3 4.0±0.3  4.4±0.3 4.1±0.3*   
  HDL-cholesterol 1.1±0.1 1.0±0.1  1.1±0.1 1.1±0.1  1.1±0.1 1.1±0.1   
  LDL-cholesterol 2.6±0.3 2.6±0.3  2.6±0.3 2.5±0.3  2.7±0.3 2.6±0.3   
  Triacylglycerol‡ 1.6±0.2 1.5±0.2  1.5±0.2 1.4±0.2  1.6±0.2 1.4±0.1*   
Blood pressure (mmHg)           
  Systolic 139±3 142±4   137±4 137±4  142±5 136±4   
  Diastolic 82±2 84±2  82±3 84±2  84±3 79±2   
Glycaemic control           
  HbA1c (%) 6.6±0.3 6.6±0.3  6.7±0.3 6.6±0.4  6.6±0.3 6.5±0.3   
  HbA1c (mmol/mol) 48.8±2.4 48.5±2.5  49.2±2.4 48.9±2.6  48.6±2.5 48.0±2.5   
  Fasting glucose (mmol/l) 7.2±0.4 7.4±0.4  7.4±0.5 7.1±0.3  7.8±0.4 7.3±0.4  0.04 
  Fasting insulin (pmol/l) 106±12 105±12  96±10 94±15  104±16 98±13   
CGM glucose over 24 h           
  Mean (mmol/l)† 7.6±0.4 8.1±0.6  8.0±0.5 7.5±0.5  8.4±0.6 7.7±0.5§  0.04 
  Minimum (mmol/l) 5.0±0.3 4.7±0.5  4.8±0.3 4.5±0.4  5.2±0.5 4.9±0.4   
  Maximum (mmol/l)† 12.4±0.6 14.0±1.0  13.4±0.9 13.6±0.9  14.1±0.8 12.3±0.6*  0.01 
  Glucose <4.0 mmol/l (% 
of time) 
1.4±0.9 2.8±1.2  3.3±2.1 5.3±2.2  4.2±1.9 4.8±2.1    
  Glucose >10.0 mmol/l (% 
of time)† 
15.7±4.2 24.2±6.5  21.8±5.2 18.6±5.1  28.1±6.8 18.6±4.9§  0.03 
  MAGE (mmol/l)† 5.2±0.4 6.4±0.6  6.5±0.7 6.5±0.7  7.1±0.6 5.4±0.4*  0.01 
Systemic inflammation           
  hs-CRP (nmol/l) 15.6±3.9 15.6±3.1  23.1±5.9 21.8±5.3  15.0±2.8 16.3±3.4   
  IFN-γ (pg/ml) 3.3±0.4 4.0±0.9  3.4±0.6 3.7±0.5  3.4±0.6 3.8±0.9   
  TNF-α (pg/ml) 2.9±0.2 2.9±0.2  3.1±0.2 3.1±0.3  2.9±0.2 2.9±0.2   
Systemic oxidative stress           
  8-iso PGF2α (pg/mg 
creatinine) 
1007±65 1047±94  1148±12
7 
1051±114  1257±15
2 
1090±84   
Data are mean ± SEM 
*p<0.05 and §p<0.10 for within-group pre vs post; †p<0.05 for intervention × time interaction; ‡p<0.05 for main effect of time 
Table 2 Association between markers of glycaemic control and urinary 8-iso PGF2α 
Marker Β 
value 
95% CI p value r2 
Baseline     
 Urinary 8-iso PGF2α  (pg/mg 
creatinine) 
    
  Mean glucose (mmol/l) −39.7 −115.4, 36.1 0.31 0.15 
  Minimum glucose (mmol/l) −156.1 −238.5, 
−73.7 
<0.001 0.38 
  Maximum glucose (mmol/l) −0.2 −30.1, 29.7 0.99 <0.01 
  Glucose < 4.0 mmol/l (% of time) 32.4 11.3, 53.4 0.003 0.32 
  Glucose >10.0 mmol/l (% of time) −4.2 −11.4, 3.0 0.25 0.14 
  MAGE (mmol/l) 34.4 −19.9, 88.7 0.21 0.08 
∆ Change     
 ∆ Urinary 8-iso PGF2α (pg/mg 
creatinine) 
    
  ∆ Mean glucose (mmol/l) 28.7 −52.3, 109.8 0.49 0.01 
  ∆ Minimum glucose (mmol/l) −27.4 −122.3, 67.4 0.57 0.01 
  ∆ Maximum glucose (mmol/l) 32.9 −1.7, 67.5 0.06 0.09 
  ∆ Glucose < 4.0 mmol/l (% of time) 8.0 −11.8, 27.9 0.43 0.02 
  ∆ Glucose >10.0 mmol/l (% of 
time) 
2.6 −3.7, 8.8 0.42 0.02 
  ∆ MAGE(mmol/l) 31.5 −10.0, 73.1 0.14 0.06 
Associations were assessed using linear regression analyses. Crude p values are provided  
Fig. 1 Changes (post − pre-intervention) in CGM variables measured over 24 h. (a) Mean 
glucose. (b) Minimum (min.) glucose. (c) Maximum (max.) glucose. (d) Time spent in 
hypoglycaemia (glucose <4.0 mmol/l, % of time). (e) Time spent in hyperglycaemia (glucose >10.0 
mmol/l, % of time). (f) MAGE. White bars, CON; grey bars, CWT; black bars, IWT. Data are 
presented as mean ± SEM. Statistical differences were analysed by two-way repeated measures 
ANOVA when comparing changes within groups, *p<0.05 and §p=0.08; one-way repeated-
measures ANOVA of Δ values when comparing differences between groups, †p<0.05, ††p<0.01 
 
Fig. 2 The association between (a) baseline levels of urinary 8-iso PGF2α and minimum blood 
glucose and (b) baseline concentrations of urinary 8-iso PGF2α and time spent in hypoglycaemia 
(over 24 h period). Circles, CON; crosses, CWT; triangles, IWT. Numbers indicate the unique 
participant identification number 
 
 
